Pharmacologic cardioversion with intravenous amiodarone is likely safe in neurocritically Ill patients

Highlights • We evaluated the safety of cardioversion of new onset neurogenic atrial fibrillation in the brain injured patient using intravenous amiodarone. • We found that pharmacologic cardioversion with intravenous amiodarone without anticoagulation is likely safe in the brain injured patient. •...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical neuroscience 2017-05, Vol.39, p.59-61
Main Authors: Su, Michael, Seki, David, Moheet, Asma M
Format: Article
Language:English
Subjects:
Administration, Intravenous
Aged
Aged, 80 and over
Amiodarone
Amiodarone - administration & dosage
Amiodarone - adverse effects
Anti-Arrhythmia Agents - administration & dosage
Anti-Arrhythmia Agents - adverse effects
Arrhythmias, cardiac
Atrial fibrillation
Atrial Fibrillation - diagnosis
Atrial Fibrillation - drug therapy
Atrial Fibrillation - physiopathology
Brain injuries, complications
Cardioversion
Critical Illness - therapy
Electric Countershock - methods
Female
Follow-Up Studies
Humans
Male
Middle Aged
Nervous System Diseases - diagnosis
Nervous System Diseases - drug therapy
Nervous System Diseases - physiopathology
Neurology
Prospective Studies
Retrospective Studies
Risk Factors
Sympathetic nervous system, pathology
Thromboembolism - chemically induced
Thromboembolism - diagnosis
Thromboembolism - physiopathology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • We evaluated the safety of cardioversion of new onset neurogenic atrial fibrillation in the brain injured patient using intravenous amiodarone. • We found that pharmacologic cardioversion with intravenous amiodarone without anticoagulation is likely safe in the brain injured patient. • Intravenous amiodarone may be considered for the treatment of atrial fibrillation in the brain injured patient.
ISSN:0967-5868
1532-2653
DOI:10.1016/j.jocn.2017.01.014